Trade CRSP stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
CRISPR Therapeutics AG Common Shares (CRSP) is trading at US$56.56, down 1.33% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$5.75B. Over the past 52 weeks, CRSP has traded between US$44.12 and US$78.48. On Syfe you can trade CRSP with $0 commission and add it to your watchlist.
| Previous close | US$57.33 |
|---|---|
| Market cap | US$5.75B |
| 52-week range | US$44.12 – US$78.48 |
| Volume | 3.38M |
| Exchange | US |
Add to Watchlist
Set Price Alert
CRISPR Therapeutics AG Common Shares
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Year: 2016
Crispr Therapeutics Posts Quiet Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says
Aug 4, 3:49 PM · MT Newswires
-- Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M
Aug 3, 8:17 PM · MT Newswires
-- Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M
May 4, 8:32 PM · MT Newswires
Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing
Mar 24, 9:43 PM · MT Newswires
Stay on top of CRSP
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
